Skip to content

Atreca, Inc.

Delisted

CIK 1532346fmd_17JXYGPRF0CNPJ8VQAH7B18SPYManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2018 to Sep 30, 2023, 22 periods

Income Statement · Annual · Millions · USD
Line itemFY2018FY2019FY2020FY2021FY2022
Research and development3355627867
Total operating expenses40738911099
Interest expense0000–
Interest and investment income13101
Income before taxes(38)(67)(86)(109)(97)
Income tax expense(0)000–
Net income from continuing operations(38)(67)(86)(109)–
Net income(38)(67)(86)(109)(97)
Atreca, Inc. financial statements · FinancialMD